Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1004-1012

  Cheng, Rong Jie ^a   Deng, Wei Guo ^b   Niu, Chun Bo ^c   Li, Yi Yang ^a   Fu, Yan ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Research Center for Genomic Medicine   (China)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

CD74; Cervical carcinoma; ELISA; Immunohistochemistry; Macrophage migration inhibitory factor (MIF)

Indexed keywords

CD34 ANTIGEN; CD74 ANTIGEN; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DENSITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WESTERN BLOTTING;

ADULT; AGED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MIDDLE AGED; NEOPLASM STAGING; UTERINE CERVICAL NEOPLASMS;

EID: 83055196817     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31821c45b7     Document Type: Article

References (20)

1. Phoophitphong T, Hanprasertpong J, Dechsukhum C, et al. Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. J Obstet Gynaecol Res. 2007;33:840Y848. (Pubitemid 350086518)
2. Randall LM, Monk BJ, Darcy KM, et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112:583Y589.
3. Lee JS, Kim HS, Park JT, et al. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal Quant Cytol Histol. 2003;25:303Y311. (Pubitemid 38044607)
4. Xu X, Wang B, Ye C, et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 2008;261:147Y157. (Pubitemid 351253721)
5. He XX, Yang J, Ding YW, et al. Increased epithelial and serum expression of migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 2006;55:797Y802. (Pubitemid 43764549)
6. White ES, Flaherty KR, Carskadon S, et al. Macrophage migration inhibitory factor and CXC chemokine expression in nonYsmall cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9:853Y860. (Pubitemid 36182624)
7. Akbar SM, Abe M, Murakami H, et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 2001;171:125Y132. (Pubitemid 32772798)
8. Krockenberger M, Engel JB, Kolb J, et al. Macrophage migration inhibitory factor expression in cervical cancer. J Cancer Res Clin Oncol. 2010;136:651Y657.
9. Hudson JD, Shoaibi MA, Maestro R, et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J ExpMed. 1999;190:1375Y1382.
10. Fingerle-Rowson G, Petrenko O. MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div. 2007;2:22.
11. Ren Y, Law S, Huang X, et al. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 2005;242:55Y63. (Pubitemid 40917968)
12. McClelland M, Zhao L, Carskadon S, et al. Expression of CD74, the receptor for macrophage migration inhibitory factor, in nonYsmall cell lung cancer. Am J Pathol. 2009;174:638Y646.
13. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res. 2004;10:6606Y6611. (Pubitemid 39346557)
14. Nagata S, Jin YF, Yoshizato K, et al. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy. Ann Surg Oncol. 2009;16:2531Y2538.
15. Sun de J, Liu Y, Lu DC, et al. Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. Hum Pathol. 2007;38:1047Y1056. (Pubitemid 46899148)
16. Ishigami S, Natsugoe S, Tokuda K, et al. Invariant chain expression in gastric cancer. Cancer Lett. 2001;168:87Y91. (Pubitemid 32463917)
17. Henne C, Schwenk F, Koch N, et al. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunology. 1995;84:177Y182.
18. Roche PA, Teletski CL, Stang E, et al. Cell surface HLA-DRYinvariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci U S A. 1993;90:8581Y8585. (Pubitemid 23277713)
19. Beswick EJ, Pinchuk IV, Suarez G, et al. Helicobacter pylori. CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol. 2006;176: 6794Y6801. (Pubitemid 43787862)
20. Meyer-Siegler KL, Iczkowski KA, Leng L, et al. Inhibition of macrophage migration inhibitory factor or its. Receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol. 2006;177:8730Y8739. (Pubitemid 44893839)